Constellation Pharmaceuticals focuses on developing novel cancer treatments that target abnormal gene expression and drug resistance. Their lead products, CPI-0610 and CPI-1205, inhibit specific proteins and enzymes to promote antitumor activity. In July 2021, Constellation Pharmaceuticals was acquired by MorphoSys, a global biopharmaceutical company specializing in innovative cancer medicines. This acquisition strengthened MorphoSys' position in hematology and oncology. Constellation Pharmaceuticals' technology platform in epigenetics has potential applications in other therapeutic areas such as autoimmune, inflammatory, and neurological diseases.